Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions

Spinal Cord. 1999 Sep;37(9):634-7. doi: 10.1038/sj.sc.3100909.

Abstract

Objective: To investigate the effect of L-dopa on the PLM/h index of spinal cord injured subjects.

Setting: São Paulo, Brazil.

Methods: Thirteen male volunteers with spinal cord section between T7 - T12, and mean age of 31.6+/-8.3 years participated in the study. L-dopa or placebo were administered for 30 days, 1 h before the volunteers went to sleep, in a double blind, crossover design. Polysomnographic recordings were performed on ten occasions: Phase 1: Basal night, following an adaptation night at the sleep laboratory; phase 2: after 1, 7, 21 and 30 days of L-dopa administration; phase 3: first night of L-dopa or placebo withdrawal; phase IV: 1, 7, 21 and 30 days after placebo ingestion.

Results: The index of PLM/h on the first night of L-dopa or placebo withdrawal (phase III) was lower than on both the basal night and the first night of L-dopa treatment. At the time of polysomnographic analysis, volunteers were divided into two groups: index of PLM/h below five and those whose index was above five. Comparison between L-dopa and placebo treatments revealed that only those volunteers with an index above five revealed a reduction in PLM in L-dopa.

Conclusion: These results indicate that despite the spinal cord lesions, L-dopa treatment is capable of minimizing PLM during sleep.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benserazide / therapeutic use*
  • Cross-Over Studies
  • Dopamine Agonists / therapeutic use*
  • Double-Blind Method
  • Humans
  • Levodopa / therapeutic use*
  • Male
  • Movement Disorders / drug therapy*
  • Movement Disorders / etiology
  • Nocturnal Paroxysmal Dystonia / drug therapy*
  • Nocturnal Paroxysmal Dystonia / etiology
  • Paraplegia / complications*
  • Polysomnography
  • Restless Legs Syndrome / drug therapy*
  • Restless Legs Syndrome / etiology

Substances

  • Dopamine Agonists
  • Levodopa
  • Benserazide